PLYMOUTH, Minnesota — Lumen Biomedical, which makes catheters to break and clear blockages in the veins, is raising $4 million, according to a filing with the Securities and Exchange Commission.
Lumen this year has struck exclusive distribution agreements for its two devices: the FiberNet System, which breaks and then captures blockages in the carotid artery in the head and neck, and the Xtract Catheter which can be guided around a vein to remove blockages including clots throughout the body. Invetec started distributing FiberNet in January (pdf) and Volcano started distributing Xtract in May.
Both devices have Food and Drug Administration and European approvals. They were approved by the FDA last year.
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.